# Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

> **NCT05272150** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 213 (actual)

## Conditions studied

- Plaque Psoriasis
- Scalp Psoriasis

## Interventions

- **DRUG:** Guselkumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05272150
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-13
- **Primary completion:** 2025-05-30
- **Final completion:** 2025-05-30
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05272150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05272150, "Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05272150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*